Study:

C₆₀ fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue

Conclusion

The use of C₆₀FAS, even at a low therapeutic dose (0.1–0.15 mg/kg) leads to a reduction in the recovery time of the muscle contraction force (after its complete exhaustion state) on the one hand, and an increase in the time of the muscle active work (endurance) until fatigue development on the other. This result illustrates the effect of C₆₀FAS, along with other possible mechanisms, on prooxidant-antioxidant homeostasis in the muscle tissue of rats.

For the full article:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237293/?fbclid=IwAR0ZQbo8bSy91toCKEakERud5eQNhzMsn11nADZ1BNYnVy7HGWxKNroZ43I